Mounjaro KwikPen 5mg: the second step in your treatment

Step 1: why 2.5mg comes first, and what shifts when you move to 5mg

A question our prescribers hear regularly is whether starting at 2.5mg means the treatment is not working yet. It does not. The opening four weeks exist so your digestive system can adjust to tirzepatide before the dose rises. Nausea, if it appears at all, tends to be mildest at that lower level, and you can find full device and dosing details on the Mounjaro KwikPen 2.5mg page. Moving to 5mg is the moment the treatment begins to do its principal job: activating both GIP and GLP-1 receptors to reduce appetite and slow how quickly food leaves the stomach.

Most people notice the appetite-suppressing effect more clearly in the first week or two on 5mg. Portions that felt comfortable before may feel like too much; meals may leave you fuller for longer. That shift is the mechanism working as intended, not a cause for concern. It can catch people off guard if nobody has mentioned it in advance. The full Mounjaro titration schedule explains each step in the sequence and what to expect as doses continue to rise.

The NHS medicines page for tirzepatide gives a clear patient-level summary of how the medicine works and what side effects to watch for at any dose.

Step 2: using the 5mg KwikPen correctly, injection sites and technique

The KwikPen is pre-filled and pre-set; you do not draw up a dose or adjust anything on the device. Each press of the button delivers one 5mg dose. The pen contains four doses, so one pen covers the whole four-week period between dose reviews.

Inject subcutaneously (into fatty tissue just under the skin) in the abdomen, thigh or upper arm. Rotate sites each week so no single area becomes tender or develops changes in the skin. Pinch the skin gently, press the pen flat against it, hold the button until the injection is complete, and keep the pen in place for a few seconds afterwards. The Patient Information Leaflet included with your pen walks through the full technique; read it before your first injection at this dose, even if you feel confident from the 2.5mg pen.

If you have any uncertainty about technique or are switching injection sites for the first time, the prescribers accessible through our support team can help, priority aftercare is available seven days a week.

Step 3: side effects that can appear at 5mg, and when to seek help

Gastrointestinal side effects are the most commonly reported at this dose: nausea, loose stools, constipation, burping and an uncomfortable sense of fullness. They tend to peak in the first week after each dose change, then settle. Eating smaller portions more slowly, staying well hydrated and avoiding high-fat or heavily spiced food on injection day can all reduce their intensity. Fatigue, headache and mild dizziness are also reported, particularly in the first week.

One side effect worth knowing about specifically is acute pancreatitis. It is uncommon, but the MHRA issued a Drug Safety Update in January 2026 highlighting it as a known risk with GLP-1 medicines. Severe, persistent stomach pain that spreads toward the back (with or without vomiting) needs urgent medical attention. Do not wait to see if it passes. Other reasons to contact a doctor promptly include signs of a serious allergic reaction, symptoms of gallbladder problems, or significant dehydration caused by prolonged vomiting or diarrhoea. You can report any suspected side effect through the MHRA Yellow Card scheme.

Questions about whether a specific symptom warrants pausing the 5mg pen or adjusting timing should go to your prescriber or the Patient Information Leaflet, not to a general guide like this one.

Step 4: where 5mg sits in the longer picture, eligibility and next doses

Under the UK licence, Mounjaro is available for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. BMI alone does not confirm suitability; a prescriber weighs the full clinical picture before approving treatment at any dose.

After four weeks at 5mg, the standard schedule moves to 7.5mg. You can read about that transition on the Mounjaro KwikPen 7.5mg page. The sequence continues through the Mounjaro KwikPen 10mg, 12.5mg and Mounjaro KwikPen 15mg, with dose increases always subject to clinical review. Some people stay at 5mg longer if side effects need more time to settle, that is a clinical decision, not a failure to progress.

In the SURMOUNT-1 trial, participants who reached the 15mg maintenance dose lost an average of around 20–21% of body weight over 72 weeks. Those earlier doses, 5mg included, are part of how the body is brought gradually to the therapeutic level where those results were achieved, as NICE noted in its appraisal of tirzepatide (NICE TA1026).

If you are weighing up the cost of private Mounjaro treatment at any dose, the Mounjaro cost guide covers what private prices typically include and how to read them. When you are ready to talk to a prescriber about your own situation, you can check your eligibility through a free consultation at any point.